Centaurus Financial’s Opus Genetics IRD Stock Holding History

Centaurus Financial’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4	Closed	–	–	2096
2018 Q2	$0	Buy	+4	New	+$352	﹤0.01%	2422

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

HVIA

Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return

BMC

Benin Management Corp Wilton, Connecticut $494M AUM 25.95% 1-Year Est. Return

Centaurus Financial's IRD Position: Q3 2018 in Review

Centaurus Financial sold out of Opus Genetics (IRD) in Q3 2018, closing a stake of 4 shares.

Centaurus Financial first reported a position in IRD in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 27 funds tracked by Wall St. Rank hold IRD as of Q3 2018.

Centaurus Financial reported no remaining Opus Genetics position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 4 Opus Genetics shares in Q3 2018.
Centaurus Financial first reported a position in Opus Genetics in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Opus Genetics position peaked at $0 in Q2 2018.
27 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.